Basilea begins BAL30072 pharmacokinetic Phase 1 study
The injectable sulfactam antibiotic has the potential to target clinically relevant gram-negative bacteria resistant to multiple drugs including Pseudomonas or Acinetobacter species. Basilea chief medical officer Prof. Achim
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.